Company Overview
Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines, with a specific focus on evaluating natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis within a palliative care context. The company operates within the Healthcare sector and the Biotechnology industry, positioning itself as a specialized entity focused on psychedelic therapeutics and palliative research applications. As of the latest data, Psyence Biomedical Ltd. holds a market capitalization of $5.87M and employs 12 individuals to execute its research and development initiatives. The combination of a sub-$6 million market cap and N/A annual revenue figures indicates that the company is a micro-cap entity operating in the early-stage development phase, where capital is primarily allocated toward clinical trials and product formulation rather than commercial scale-up. This small scale reflects the typical characteristics of a pre-commercial biotechnology firm that has not yet generated significant sales revenue to offset its substantial operating expenditures.
Financial Health
The company reports N/A for revenue (TTM) and a net income (TTM) of $-3,941,597, while its EBITDA stands at $-4,145,455. The absence of reported revenue alongside significant net losses highlights a cost structure dominated by research and development expenses rather than commercial operations, which is standard for firms in the biotechnology industry that are still validating their lead product candidates. Psyence Biomedical Ltd. maintains a free cash flow of $-4,006,023, indicating a consistent burn rate that reflects heavy investment in its pipeline without current commercial income to support operations. The company's gross margin is 0.0%, its operating margin is 0.0%, and its profit margin is 0.0%, all of which align with the business model of a pre-revenue biotechnology company where costs exceed revenues due to the lack of sales volume. Despite the negative earnings, the firm holds $7.15M in cash and has N/A for total debt, resulting in a debt-to-equity ratio of N/A which suggests a conservative balance sheet free from traditional interest-bearing obligations. The current ratio is 8.09, a figure that indicates strong short-term liquidity relative to current liabilities, providing ample buffer to fund ongoing operations and clinical studies. Return on Equity is -74.3% and Return on Assets is -34.4%, metrics that reveal the company is currently eroding shareholder value and utilizing assets to generate losses rather than profits, a common characteristic during the initial phases of drug development before regulatory approval is secured.
Valuation Assessment
The trailing P/E ratio is N/A and the forward P/E is N/A, reflecting the fact that the company has not yet achieved profitability required to calculate a standard earnings-based multiple. The price-to-book ratio is 0.06, a figure that indicates the market values the company at a fraction of its net asset book value, suggesting that the market is pricing in the high risk of the unproven asset base and the lack of tangible assets backing the current share price. Price-to-sales is N/A and the EV/EBITDA is 1.54, providing an alternative valuation perspective that incorporates enterprise value relative to earnings before interest, taxes, depreciation, and amortization despite the negative earnings. The stock has a 52-week high of $468.36 and a 52-week low of $1.92, creating an extreme trading range that underscores the high volatility typical of small-cap biotechnology stocks with speculative growth profiles. While the current price is not explicitly provided in the available facts to calculate a precise percentage, the massive disparity between the high and low suggests the stock is currently trading far below the 52-week high, reflecting investor caution regarding the company's ability to commercialize its botanical psilocybin-based medicines. The beta is 0.36, which indicates that the stock's price volatility is significantly lower than the broader market, likely due to its low market capitalization and limited liquidity rather than a lack of risk.
Growth & Income
Revenue growth year-over-year is N/A and earnings growth year-over-year is N/A, as the company has not yet generated sufficient revenue or earnings to establish a historical growth trajectory. Since the company does not pay dividends, the dividend yield is N/A and the payout ratio is 0.0%, meaning that all available earnings are theoretically available for reinvestment, though the company is currently operating at a loss. Because the company does not distribute income to shareholders, it follows the standard biotechnology model of reinvesting capital into research, development, and clinical trials to advance its lead product candidate rather than paying out returns. The overall growth and income profile is characterized by zero current revenue, negative earnings growth, and no dividend income, reflecting the status of a pre-revenue entity focused entirely on advancing its pipeline of botanical psilocybin-based psychedelic medicines.